These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38237108)

  • 1. Multicenter Validation of the Charcot-Marie-Tooth Functional Outcome Measure.
    Mandarakas MR; Eichinger KJ; Bray P; Cornett KMD; Shy ME; Reilly MM; Ramdharry GM; Scherer SS; Pareyson D; Estilow T; McKay MJ; ; Herrmann DN; Burns J
    Neurology; 2024 Feb; 102(3):e207963. PubMed ID: 38237108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reliability of the Charcot-Marie-Tooth functional outcome measure.
    Bray P; Cornett KMD; Estilow T; Pareyson D; Zuccarino R; Skorupinska M; Pipis M; Sowden JE; Scherer S; Reilly MM; Shy ME; Herrmann DN; Burns J; Eichinger KJ
    J Peripher Nerv Syst; 2020 Sep; 25(3):288-291. PubMed ID: 32844461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of the Charcot-Marie-Tooth Disease Infant Scale.
    Mandarakas MR; Menezes MP; Rose KJ; Shy R; Eichinger K; Foscan M; Estilow T; Kennedy R; Herbert K; Bray P; Refshauge K; Ryan MM; Yiu EM; Farrar M; Sampaio H; Moroni I; Pagliano E; Pareyson D; Yum SW; Herrmann DN; Acsadi G; Shy ME; Burns J; Sanmaneechai O
    Brain; 2018 Dec; 141(12):3319-3330. PubMed ID: 30476010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Charcot-Marie-Tooth Functional Outcome Measure (CMT-FOM).
    Eichinger K; Burns J; Cornett K; Bacon C; Shepherd ML; Mountain J; Sowden J; Shy R; Shy ME; Herrmann DN
    Neurology; 2018 Oct; 91(15):e1381-e1384. PubMed ID: 30232254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability.
    Burns J; Ouvrier R; Estilow T; Shy R; Laurá M; Pallant JF; Lek M; Muntoni F; Reilly MM; Pareyson D; Acsadi G; Shy ME; Finkel RS
    Ann Neurol; 2012 May; 71(5):642-52. PubMed ID: 22522479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic Variability of Childhood Charcot-Marie-Tooth Disease.
    Cornett KM; Menezes MP; Bray P; Halaki M; Shy RR; Yum SW; Estilow T; Moroni I; Foscan M; Pagliano E; Pareyson D; Laurá M; Bhandari T; Muntoni F; Reilly MM; Finkel RS; Sowden J; Eichinger KJ; Herrmann DN; Shy ME; Burns J;
    JAMA Neurol; 2016 Jun; 73(6):645-51. PubMed ID: 27043305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT): A Protocol to Address Clinical Trial Readiness in CMT1A.
    Eichinger K; Sowden JE; Burns J; McDermott MP; Krischer J; Thornton J; Pareyson D; Scherer SS; Shy ME; Reilly MM; Herrmann DN
    Front Neurol; 2022; 13():930435. PubMed ID: 35832173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Charcot-Marie-Tooth disease and related inherited neuropathies.
    Murakami T; Garcia CA; Reiter LT; Lupski JR
    Medicine (Baltimore); 1996 Sep; 75(5):233-50. PubMed ID: 8862346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the Italian version of the Charcot-Marie-Tooth Health Index.
    Pisciotta C; Ciafaloni E; Zuccarino R; Calabrese D; Saveri P; Fenu S; Tramacere I; Genovese F; Dilek N; Johnson NE; Heatwole C; Herrmann DN; Pareyson D;
    J Peripher Nerv Syst; 2020 Sep; 25(3):292-296. PubMed ID: 32511835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ascorbic acid for the treatment of Charcot-Marie-Tooth disease.
    Gess B; Baets J; De Jonghe P; Reilly MM; Pareyson D; Young P
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011952. PubMed ID: 26662471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients.
    Mannil M; Solari A; Leha A; Pelayo-Negro AL; Berciano J; Schlotter-Weigel B; Walter MC; Rautenstrauss B; Schnizer TJ; Schenone A; Seeman P; Kadian C; Schreiber O; Angarita NG; Fabrizi GM; Gemignani F; Padua L; Santoro L; Quattrone A; Vita G; Calabrese D; ; Young P; Laurà M; Haberlová J; Mazanec R; Paulus W; Beissbarth T; Shy ME; Reilly MM; Pareyson D; Sereda MW
    Neuromuscul Disord; 2014 Nov; 24(11):1003-17. PubMed ID: 25085517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Employment status of patients with Charcot-Marie-Tooth type 1A.
    Bjelica B; Brankovic M; Bozovic I; Palibrk A; Kacar A; Rakocevic-Stojanovic V
    Acta Neurol Belg; 2022 Jun; 122(3):641-646. PubMed ID: 33491123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported disease burden in the Accelerate Clinical Trials in Charcot-Marie-Tooth Disease Study.
    Rehbein T; Purks J; Dilek N; Behrens-Spraggins S; Sowden JE; Eichinger KJ; ; Burns J; Pareyson D; Scherer SS; Reilly MM; Shy ME; McDermott MP; Heatwole CR; Herrmann DN
    J Peripher Nerv Syst; 2024 Dec; 29(4):487-493. PubMed ID: 39390667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial.
    Pareyson D; Reilly MM; Schenone A; Fabrizi GM; Cavallaro T; Santoro L; Vita G; Quattrone A; Padua L; Gemignani F; Visioli F; Laurà M; Radice D; Calabrese D; Hughes RA; Solari A; ;
    Lancet Neurol; 2011 Apr; 10(4):320-8. PubMed ID: 21393063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic epidemiology of Charcot-Marie-Tooth disease.
    Braathen GJ
    Acta Neurol Scand Suppl; 2012; (193):iv-22. PubMed ID: 23106488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease-specific wearable sensor algorithms for profiling activity, gait, and balance in individuals with Charcot-Marie-Tooth disease type 1A.
    Dinesh K; White N; Baker L; Sowden JE; Behrens-Spraggins S; Wood E; Charles J; Herrmann DN; Sharma G; Eichinger K
    J Peripher Nerv Syst; 2023 Sep; 28(3):368-381. PubMed ID: 37209301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome measures in the clinical evaluation of ambulatory Charcot-Marie-Tooth 1A subjects.
    Mori L; Prada V; Signori A; Pareyson D; Piscosquito G; Padua L; Pazzaglia C; Fabrizi GM; Smania N; Picelli A; Schenone A;
    Eur J Phys Rehabil Med; 2019 Feb; 55(1):47-55. PubMed ID: 29898585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical presentation of Charcot-Marie-Tooth disease 1A: A case report.
    Kulkarni SD; Sayed R; Garg M; Patil VA
    Neuromuscul Disord; 2015 Nov; 25(11):916-9. PubMed ID: 26432165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Validation of the Pediatric Charcot-Marie-Tooth Disease Quality of Life Outcome Measure.
    Ramchandren S; Wu TT; Finkel RS; Siskind CE; Feely SME; Burns J; Reilly MM; Estilow T; Shy ME;
    Ann Neurol; 2021 Feb; 89(2):369-379. PubMed ID: 33222249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional outcome measures for infantile Charcot-Marie-Tooth disease: a systematic review.
    Mandarakas MR; Rose KJ; Sanmaneechai O; Menezes MP; Refshauge KM; Burns J
    J Peripher Nerv Syst; 2018 Jun; 23(2):99-107. PubMed ID: 29521025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.